Open an account

OncoSec Medical

ONCSQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About ONCSQ

OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. The company is headquartered in Ewing, New Jersey and currently employs 40 full-time employees. The company went IPO on 2015-05-29. The firm is focused on developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate disease. Its lead immunotherapy investigational product candidate-TAVO (tavokinogene telseplasmid)-enables the intratumoral delivery of DNA-based interleukin 12 (IL-12), a naturally occurring protein with immune-stimulating functions. The therapeutic approach TAVO-EP, which employs electroporation, is designed to produce a localized expression of IL-12 in the tumor microenvironment and, thereby, stimulate the immune system to target and attack tumors.

Employees
40
Headquarters
Ewing, New Jersey
Listed
May 29, 2015
Sector
Health Care
Industry
Biotechnology
Website
oncosec.com

ONCSQ key statistics

Market cap
6
Price-earnings ratio
—
Dividend yield
—
Average volume
1.08K
Volume
23
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.0001
52 Week low
$0.00

OncoSec Medical (ONCSQ) at a glance

As of Oct 15, 2026, OncoSec Medical (ONCSQ) shares are priced at $0.00, giving the company a market cap of 6.

Volume so far is 23 shares, below the average of 1.08K shares a day.

Over the past year OncoSec Medical has ranged from $0.00 to $0.0001, and now sits 0% of the way up that range.

OncoSec Medical met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q1 FY23 it reported -$4.50 per share against an estimate of -$5.05.

ONCSQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 12.0% on average.

  1. Q2 FY21: reported -$8.14 per share against an estimate of -$8.16
  2. Q3 FY21: reported -$6.16 per share against an estimate of -$6.97
  3. Q4 FY21: reported -$6.38 per share against an estimate of -$6.50
  4. Q1 FY22: reported -$5.50 per share against an estimate of -$8.38
  5. Q2 FY22: reported -$5.50 per share against an estimate of -$6.00
  6. Q3 FY22: reported -$3.52 per share against an estimate of -$4.08
  7. Q4 FY22: reported -$4.62 per share against an estimate of -$5.44
  8. Q1 FY23: reported -$4.50 per share against an estimate of -$5.05

Similar companies

Companies in the same industry as OncoSec Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.